PROFESSIONAL LABELLING ANYWHERE, ANYTIME: DYMO® INTRODUCES NEW LABELMANAGER EXECUTIVE 640 CB

DYMO®, a leader in innovative labeling solutions, proudly announces the launch of the new LabelManager Executive 640 CB. It is designed for professionals seeking a fast, efficient, and reliable labeling solution for various work environments, from offices to the medical sector, with a strong emphasis on ease of use. The LabelManager Executive 640 CB enables users to print labels faster, saving valuable time on labeling tasks and boosting productivity across industries.
User-Friendly Design and Versatile Connectivity
In today's fast-paced work environment, organization and clarity are crucial. The LabelManager Executive 640 CB addresses these needs with a compact design and a rechargeable lithium-ion battery, making it perfect for both office use and on-the-go labeling. Its high-resolution (240*320 pixels RGB; 143 ppi) display ensures clear and readable labels, while the intuitive menu simplifies label creation and customization.
The device offers multiple connectivity options, including Bluetooth® Low Energy and USB-C, allowing seamless integration with iOS and Android devices, as well as computers without the need for manual pairing. It supports the DYMO® LabelManager® Executive Connect app and desktop software, providing virtually unlimited label storage. Compatible with both D1 standard and Durable tapes in widths from 6 (1/4') to 24 mm (1'), and available in various colors and finishes, the LabelManager Executive 640 CB is a versatile solution for diverse labeling needs.
Versatile and Sustainable Usage
The LabelManager Executive 640 CB is ideal for a wide range of applications, including office organization, production component tracking, retail pricing, and medical device and patient identification.
DYMO® is committed to sustainability, with the device's packaging made from 70% recycled material and the housing and cassette packaging from at least 80% recycled material, promoting environmentally friendly solutions.
Availability
The LabelManager Executive 640 CB is available now in two versions: the Kit Box and the Gift Box. Both include the LabelManager, a battery pack, a USB-C to USB-C cable, and a quick start guide. The Kit Box also includes three standard label cartridges, while the Gift Box comes with one standard label cassette.
Key Features:
Further information can be found on our website at www.dymo.com.
About Newell Brands:
Newell Brands (NASDAQ: NWL) is a leading global consumer goods company with a strong portfolio of well-known brands, including Rubbermaid, Sharpie®, Graco®, Coleman®, Rubbermaid Commercial Products®, Yankee Candle®, Paper Mate®, FoodSaver®, Dymo®, EXPO®, Elmer's®, Oster®, NUK®, Spontex® and Campingaz®. Newell Brands is focused on delighting consumers by lighting up everyday moments.
www.newellbrands.com.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

5 hours ago

• Yahoo

Tigo Energy and BayWa r.e. Empower High-Wattage C&I Solar in Thailand

At annual ASEAN Sustainable Energy Week 2025, Tigo and BayWa r.e. collaborate on optimization, monitoring, and rapid shutdown solutions for C&I solar in Thailand. CAMPBELL, Calif., June 22, 2025--(BUSINESS WIRE)--Tigo Energy, Inc. (NASDAQ: TYGO) ("Tigo" or "Company"), a leading provider of intelligent solar and energy software solutions, today announced that the Company will share a trade show booth with BayWa r.e. at the annual ASEAN Sustainable Energy Week 2025, from July 2-4, at the QSNCC in Bangkok, Thailand. At the show, Tigo will focus on supporting Commercial and Industrial (C&I) solar installers and engineering, procurement, and construction specialists (EPCs) as enforcement of new rapid shutdown requirements begins, deploying high-wattage modules in high-irradiance regions, and ensuring Total Quality Solar (TQS) through Tigo service programs. For solar projects in hot, humid, and high-irradiance (>1000W/m2) regions like Southeast Asia, the Tigo TS4-X family of MLPE devices provides the latest in optimization, monitoring, and safety for solar installers deploying high-wattage modules, including supporting the increased backside gains of modern bifacial modules. The TS4-X product line gives installers more freedom to deploy the modules that deliver the power and performance for their customer deployments, reduce labor costs with a no-bolt design and no need for additional ground wiring, and contribute to improving Levelized Cost Of Energy (LCOE) in the large-scale solar sector. Tigo MLPE devices pair with an industry-leading list of third-party solar inverters to deliver design and installation flexibility for solar installers and EPCs. "Thailand's rooftop solar market is growing rapidly and so is the demand for safer, smarter systems," said Junrhey Castro, managing director at BayWa r.e. Solar Systems. "As a regional distributor, we're committed to supporting this growth with reliable solutions that protect both the performance and investment of our customers. Having Tigo in our product portfolio reflects our focus on quality and innovation for solar professionals across Thailand and Southeast Asia." In Thailand, Tigo will also invite installers to enroll directly in the Tigo Green Glove service program at the BayWa r.e. booth. The Green Glove service program is a premium support experience for installers of commercial and industrial (C&I) systems that enhances the installer experience and drives quality across the solar value chain with a process that includes a set of formalized support engagements for Tigo C&I installers before, during, and after the installation. "Strong collaboration between global companies like BayWa r.e. and Tigo is part of what makes the solar ecosystem work for more installers and EPCs around the world," said Jing Tian, chief growth and revenue officer at Tigo Energy. "As with many of the pro-solar nations in Asia, we believe that products like the TS4-X and programs like Green Glove make great strides in further driving LCOE down, and Total Quality Solar up, respectively. In regions with higher-than-normal irradiance values in particular, these dynamics benefit the entire industry, from equipment manufacturer to installer, and on to the operators and asset owners." ASEAN Sustainable Energy Week 2025 attendees are invited to visit BayWa r.e. and Tigo at booth F11 from July 2-4, at the QSNCC in Bangkok, Thailand. To book an appointment with a Tigo specialist at the show, please register your interest here. About Tigo Energy Founded in 2007, Tigo Energy, Inc. (NASDAQ: TYGO) is a worldwide leader in the development and provider of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and provides products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit View source version on Contacts Technica Communications for Tigo EnergyLuis de LeonEmail: tigoenergy@

Hypebeast

5 hours ago

• Hypebeast

Hercules' DJControl Mix Ultra is a Mobile DJ Controller for ... Mobiles

In 2025, there isn't much you can't be or do if you wanted to (thanks, technology) – and if becoming aDJ's been on your list, it's never been easier. Enter the Hercules DJControl Mix Ultra: a truly compact mobileDJ controllerthat's made for, well, mobiles. Designed to work seamlessly with smartphones and small tablets, it's the latest addition to Hercules' lineup – and it delivers a ton of features at an accessible price. Weighing in at just 1.9-pounds and measuring 12.4-inches by 6.9-inches, the Mix Ultra is a super portable and lightweight DJ controller that slips easily into most standard backpacks. It's powered by a 1,000 mAh rechargeable battery that can deliver up to 10 hours of use on a single charge, and can recharge to full in one hour. The2025 CES Innovation Award-winning device connects to your phone over Bluetooth LE – the 'low energy' version of Bluetooth that maintains connectivity without using too much power – allowing users to enjoy a cable-free session for longer. It uses your phone as its audio source, letting you load up tracks you have saved on your device or play from popular streaming platforms, and comes with a splitter cable in the box that lets you connect both headphones and speakers to it – splitting the audio channels this way allows you to hear what you're mixing (in your headphones) separately to the master output (from the speakers), although its worth noting that it achieves this by creating two mono tracks. For beginners and hobbyists, at who the Mix Ultra is aimed at, this shouldn't be a big issue, and it's safe to say Hercules isn't trying to target more experienced DJs – or audio purists – with its latest product. The Mix Ultra features eight effects pads that allows users to hot cue, creates loops, play audio 'FX' among other things. One of these pads, 'Neural Mix', lets you isolate a track's stems (its individual elements, like the vocals or bassline) to use these in your own mixes, opening up a world of creativity when it comes to DJ'ing. Another pad provides pitch control, and there's even a sampler pad that allows you to add your own samples, but also comes ready with a few included for you to use. The controller has a tri-band EQ for the low, mid and high frequencies – the same kind of EQ you'd find on most basic DJ mixers – with rubber knobs that turn smoothly. And, for transport, it includes an easily removable protective travel cover that doubles-up as a phone holder once removed: you simply place the Mix Ultra on top of it, like a tray, and a handy slot for your phone takes form toward the rear. It's compatible with both iOS and Android devices and there is a companion app, 'djay', for both platforms – it's free and you can download it on theApple App StoreandGoogle Play Store. While the Hercules DJControl Mix Ultra is a far cry from the industry standard ($3,000 to 4,000 USD) controllers you'll find in clubs worldwide, it's also a fraction of the price. It packs several features that make it ideal for those just starting to explore the hobby, and fun enough for more experienced DJs who just want to play around with some beats. The Hercules DJControl Mix Ultra is available nowvia Herculespriced at £149.99 GBP / $‌219.99 USD.

Business Wire

6 hours ago

• Business Wire

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq ®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). These topline findings are from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of the STELLAR-303 phase 3 trial. The trial will proceed to the planned final analysis for the other dual primary endpoint of OS in patients without liver metastases (non-liver metastases, NLM). The safety profiles of zanzalintinib in combination with atezolizumab and of regorafenib were generally consistent with what has been previously observed, and no new safety signals were identified. The ITT population consisted of all randomized patients, regardless of the presence of liver metastases. The NLM subgroup consisted of patients who did not have active liver metastases at baseline as determined by investigator assessment. 'The STELLAR-303 results, which showed a survival benefit with the combination of zanzalintinib and atezolizumab versus regorafenib across all randomized patients with previously treated metastatic colorectal cancer, marks an important first milestone for our zanzalintinib pivotal development program,' said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. 'We look forward to discussing the findings with regulatory authorities and presenting the detailed results at an upcoming medical conference.' Secondary endpoints of STELLAR-303 include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. Exelixis plans to submit detailed results of STELLAR-303 for presentation at an upcoming medical conference. About STELLAR-303 STELLAR-303 (NCT05425940) is a global, multicenter, randomized, phase 3, open-label study that randomized 901 patients 1:1 to either zanzalintinib (100 mg) in combination with atezolizumab or regorafenib. The study includes patients with previously treated non-MSI-high metastatic CRC. The dual primary endpoints of the study are OS in the ITT population and in the NLM subgroup of patients. Presence of liver metastases at baseline for all enrolled patients was determined by investigator assessment. Secondary endpoints include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. More information about the trial is available at About Zanzalintinib Zanzalintinib is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and resistance to multiple therapies, including immune checkpoint inhibitors. With zanzalintinib, Exelixis sought to build upon its extensive experience with the target profile of cabozantinib, the company's flagship medicine, while improving key characteristics, including pharmacokinetic half-life. Zanzalintinib is currently being developed for the treatment of advanced solid tumors, including colorectal cancer, kidney cancer, head and neck cancer and neuroendocrine tumors. Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials. About CRC CRC is the third most common cancer and the second leading cause of cancer-related deaths in the U.S. 1 Approximately 154,000 new cases will be diagnosed in the U.S. with around 53,000 expected deaths from the disease in 2025. 1 CRC is most frequently diagnosed among people aged 65-74 and is more common in men and in people of non-Hispanic American Indian/Alaska Native descent. 2 Nearly a quarter of CRC cases are diagnosed at the metastatic stage, at which point the five-year survival rate is just 16.2%. 2 The liver is the most common site for CRC metastasis. Liver metastases significantly impact survival, with a median five-year survival rate of less than 14% when treated with palliative chemotherapy. 3 About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements related to: the therapeutic potential of the combination of zanzalintinib in combination with atezolizumab to improve overall survival in patients with metastatic CRC; Exelixis' plans to discuss the trial data from STELLAR-303 with regulatory authorities and to present detailed findings at an upcoming medical conference; and Exelixis' scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis' continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating zanzalintinib; Exelixis' dependence on third-party vendors for the development, manufacture and supply of zanzalintinib; Exelixis' ability to protect its intellectual property rights; market competition; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption 'Risk Factors' in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis. TECENTRIQ is a registered U.S. trademark of Genentech, a member of the Roche Group. ___________________________ 1 Key Statistics for Colorectal Cancer. ACS website. Available at: Accessed June 2025. 2 Cancer Stat Facts: Colorectal Cancer. SEER website. Available at: Accessed June 2025. 3 Ros J, Salva F, Dopazo C, et al. Liver transplantation in metastatic colorectal cancer: are we ready for it? Br J Cancer. May 2023;128(10):1797-1806.